Search results for "radiogenomics"
showing 3 items of 3 documents
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges
2021
Abstract The application of imaging biomarkers in oncology is still in its infancy, but with the expansion of radiomics and radiogenomics a revolution is expected in this field. This may be of special interest in head and neck cancer, since it can promote precision medicine and personalization of treatment by overcoming several intrinsic obstacles in this pathology. Our goal is to provide the medical oncologist with the basis to approach these disciplines and appreciate their main uses in clinical research and clinical practice in the medium term. Aligned with this objective we analyzed the most relevant studies in the field, also highlighting novel opportunities and current challenges.
The role of PET radiomic features in prostate cancer: a systematic review
2021
Aim: This systematic review aims to present the available evidence on the use of radiomic features (RFs) extracted from PET imaging in patients with prostate cancer (PCa). Materials and methods: A comprehensive literature search of studies on the utility of PET-derived RFs in patients with PCa was performed in the PubMed/MEDLINE database through February 24th, 2021 using the following search string: [“positron-emission tomography” (MeSh terms) OR “positron emission tomography computed tomography” (MeSh terms) OR “positron-emission tomography” (all fields) OR “positron emission tomography computed tomography” (all fields) OR “PET” (all fields)] AND [“radiomics” (all fields) OR “radiomic” (al…
Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas
2020
The evaluation of the isocitrate dehydrogenase (IDH) mutation status in the glioma decision-making process has diagnostic, prognostic and therapeutic implications. The aim of this study was to evaluate whether conventional magnetic resonance imaging (MRI) and apparent diffusion coefficient (ADC) can noninvasively predict the most common IDH mutational status (R132H) in GIII-astrocytomas and the overall survival (OS). Hence, twenty-two patients (9-F, 13-M) with a histological diagnosis of GIII-astrocytoma and evaluation of IDH-mutation status (12-wild type, 10-mutant) were retrospectively evaluated. Imaging studies were reviewed for the morphological feature and mean ADC values (ADCm). Stati…